Guy's and St Thomas' NHS Foundation Trust

VeinWay Closes Oversubscribed SAFE Round and Begins Series A Round

Retrieved on: 
Jeudi, septembre 7, 2023
Heart, Abstract, Medicine, SAFE, Vein, Clinical trial, DVT, Coronavirus Scientific Advisory Board, Leg, Research, Traversa, Doctor of Philosophy, Thrombectomy, MD, PTS, Physician, Cardiology, St Thomas' Hospital, Growth, Guy, Hospital, LINC, Guy's and St Thomas' NHS Foundation Trust, King's College, FDA, News, Stent, Food delivery, Birth control

OR YEHUDA, Israel, Sept. 7, 2023 /PRNewswire/ -- VeinWay has closed an oversubscribed SAFE round of investment and has opened a series A round.

Key Points: 
  • OR YEHUDA, Israel, Sept. 7, 2023 /PRNewswire/ -- VeinWay has closed an oversubscribed SAFE round of investment and has opened a series A round.
  • Today's news follows two successful compassionate use cases presented at the LINC conference in Leipzig, Germany in June 2023.
  • "We are excited about VeinWay's leadership, technology and business value proposition," said Mr. Jordan Feiger, an investor in the SAFE round.
  • VeinWay also announced today that Stephen Black, MD and Houman Jalaie, MD, PhD have joined the company's scientific advisory board.

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

Retrieved on: 
Mercredi, septembre 6, 2023
Medical genetics, FRCP, University, Royal Free Hospital, University of the Witwatersrand, BioMarin Pharmaceutical, Consultant, Keck School of Medicine of USC, Achondroplasia, Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of Southern California, BMRN, Division, University of Minnesota Medical School, SAN, NHS foundation trust, Evelina London Children's Hospital, Hospital, Haemophilia, Master of Medicine, Hemostasis, Broadcasting, Instrumentation, Pediatrics, Bachelor of Medicine, Bachelor of Surgery, Endocrinology

SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.

Key Points: 
  • R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th
    SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m.
  • ET on Tuesday, September 12, 2023.
  • BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.
  • An archived version of the remarks will also be available through the Company's website for a limited time following the event.

HLTH Is Coming: Preeminent Health Innovation Event In The U.S. Launches In Europe & Announces First Supporters

Retrieved on: 
Lundi, juin 19, 2023
Guy's and St Thomas' NHS Foundation Trust, Health, Policy, Headspace, RAI Amsterdam, ResMed, Withings, Sheba Medical Center, NHS foundation trust, Novo Nordisk, AWS, Content, AptarGroup, Shop Talk

HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.

Key Points: 
  • HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.
  • Founded by serial entrepreneur and investor, Jonathan Weiner, HLTH will be the third event he has founded to be brought to Europe at scale.
  • HLTH Europe's agenda will profile the individuals and organisations catalysing action and inspiring change across the entire European health ecosystem.
  • HLTH Europe will focus on tackling the difficult conversations and exploring the many opportunities in European health today,' said Lina Behrens, Head of Content, HLTH Europe.

HLTH Is Coming: Preeminent Health Innovation Event In The U.S. Launches In Europe & Announces First Supporters

Retrieved on: 
Lundi, juin 19, 2023
Guy's and St Thomas' NHS Foundation Trust, Health, Policy, Headspace, RAI Amsterdam, ResMed, Withings, Sheba Medical Center, NHS foundation trust, Novo Nordisk, AWS, Content, AptarGroup, Shop Talk

HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.

Key Points: 
  • HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.
  • Founded by serial entrepreneur and investor, Jonathan Weiner, HLTH will be the third event he has founded to be brought to Europe at scale.
  • HLTH Europe's agenda will profile the individuals and organisations catalysing action and inspiring change across the entire European health ecosystem.
  • HLTH Europe will focus on tackling the difficult conversations and exploring the many opportunities in European health today,' said Lina Behrens, Head of Content, HLTH Europe.

Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Retrieved on: 
Mercredi, mai 17, 2023
Biotechnology, Surgery, Health, Clinical Trials, Cardiology, Edwards, CE, Freedom, SVD, Guy's and St Thomas' NHS Foundation Trust, Calcification, Structural heart disease, Quality of life, Heart valve, Calcium, Cardiothoracic surgery, 103rd Ohio Infantry Regiment, Patient, American Association for Thoracic Surgery, Mitral valve, Physician, NHS foundation trust, IDE, Aortic stenosis, Safety, Pharmaceutical industry, Medical imaging

Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer.

Key Points: 
  • Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer.
  • Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA* aortic valved conduit, the MITRIS RESILIA* mitral valve and the SAPIEN 3 Ultra RESILIA* transcatheter aortic heart valve.
  • The latest data from the COMMENCE aortic trial join a growing library of clinical studies in support of RESILIA tissue.
  • The trial is evaluating the safety and effectiveness of Edwards' bioprosthetic aortic valve with RESILIA tissue in patients ages 18 and older with diagnosed aortic valve disease and scheduled to undergo aortic valve replacement surgery.

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

Retrieved on: 
Lundi, février 13, 2023
Achondroplasia, Cancer, NHS foundation trust, Hospital, Webcast, Guy, Evelina London Children's Hospital, PALO, Osteochondrodysplasia, Guy's and St Thomas' NHS Foundation Trust, Nursing

Dr. Irving, a key opinion leader who specializes in genetic and rare conditions and specifically in skeletal dysplasia, will provide an overview of the medical complications as well as the social and emotional impact experienced by those living with achondroplasia.

Key Points: 
  • Dr. Irving, a key opinion leader who specializes in genetic and rare conditions and specifically in skeletal dysplasia, will provide an overview of the medical complications as well as the social and emotional impact experienced by those living with achondroplasia.
  • Dr. Irving has established multidisciplinary pediatric clinics to help those with the condition, and is an active researcher, hoping to develop new treatment paradigms and potentially improve the clinical outcome of severe genetic skeletal conditions.
  • To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com .
  • A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

Schneider Electric Wins 'Cloud Transformation/MSP Project' and 'Futureproofing Initiative' of the Year' at the SDC Awards 2022

Retrieved on: 
Jeudi, décembre 1, 2022
Cloud, Software, Birmingham Women's NHS Foundation Trust, University, DCIM, Curriculum, Partnership, Electric Universe (album), Advanced Power Technologies, Digitalization, Guy's and St Thomas' NHS Foundation Trust, Life, The French Connection (production company), Trust, UPS, APT, Schneider Electric, NHS foundation trust, CPD, Birmingham Women's and Children's NHS Foundation Trust, UK, Woman, Sustainability, Great Ormond Street Hospital for Children NHS Foundation Trust, SDC, Safety, Risk management, Online shopping, Medical device

LONDON, Dec. 1, 2022 /PRNewswire/ -- Schneider Electric™, the leader in digital transformation of energy management and automation has won two categories at the prestigious 2022 Storage, Digitalisation and Cloud (SDC) Awards. Schneider Electric secured awards in the 'Futureproofing Initiative' category for its Schneider Electric University, an industry-leading professional education platform that helps to bridge the data centre sector skills gap.

Key Points: 
  • Schneider Electric secured awards in the 'Futureproofing Initiative' category for its Schneider Electric University, an industry-leading professional education platform that helps to bridge the data centre sector skills gap.
  • Schneider Electric and its Elite Partners, Advanced Power Technology, also secured a second award for the 'Cloud Transformation/MSP Project of the Year' category.
  • To date, the Schneider Electric (SE) University has delivered more than one million courses to over 650,000 data centre professionals, with +180 countries represented by its global user base.
  • In collaboration with its Elite Partners Advanced Power Technology (APT) , Schneider Electric received a second award for 'Cloud Transformation/MSP Project of the Year'.

Schneider Electric Wins 'Cloud Transformation/MSP Project' and 'Futureproofing Initiative' of the Year' at the SDC Awards 2022

Retrieved on: 
Jeudi, décembre 1, 2022
Cloud, Software, Birmingham Women's NHS Foundation Trust, University, DCIM, Curriculum, Partnership, Electric Universe (album), Advanced Power Technologies, Digitalization, Guy's and St Thomas' NHS Foundation Trust, Life, The French Connection (production company), Trust, UPS, APT, Schneider Electric, NHS foundation trust, CPD, Birmingham Women's and Children's NHS Foundation Trust, UK, Woman, Sustainability, Great Ormond Street Hospital for Children NHS Foundation Trust, SDC, Safety, Risk management, Online shopping, Medical device

LONDON, Dec. 1, 2022 /PRNewswire/ -- Schneider Electric™, the leader in digital transformation of energy management and automation has won two categories at the prestigious 2022 Storage, Digitalisation and Cloud (SDC) Awards. Schneider Electric secured awards in the 'Futureproofing Initiative' category for its Schneider Electric University, an industry-leading professional education platform that helps to bridge the data centre sector skills gap.

Key Points: 
  • Schneider Electric secured awards in the 'Futureproofing Initiative' category for its Schneider Electric University, an industry-leading professional education platform that helps to bridge the data centre sector skills gap.
  • Schneider Electric and its Elite Partners, Advanced Power Technology, also secured a second award for the 'Cloud Transformation/MSP Project of the Year' category.
  • To date, the Schneider Electric (SE) University has delivered more than one million courses to over 650,000 data centre professionals, with +180 countries represented by its global user base.
  • In collaboration with its Elite Partners Advanced Power Technology (APT) , Schneider Electric received a second award for 'Cloud Transformation/MSP Project of the Year'.

Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years

Retrieved on: 
Jeudi, novembre 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ACAAI, Review, AES, Pediatric Allergy and Immunology, Guy's and St Thomas' NHS Foundation Trust, Evelina London Children's Hospital, Parent, Diagnosis, NHS foundation trust, University of Arkansas, Therapy, Food, Hospital, News, Guy Goodwin, Safety, Medicine, OIT, Anaphylaxis, University, Patient, Peanut allergy, Death, Ageing, Medical Affairs Bureau, FDA, Peanut, American College, Pharmaceutical industry, Copper, Health insurance, Allergy, Pediatrics

The trial evaluated the efficacy and safety of PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in peanut-allergic children aged 1 to 3 years.

Key Points: 
  • The trial evaluated the efficacy and safety of PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in peanut-allergic children aged 1 to 3 years.
  • The encouraging results of the POSEIDON study indicate that PALFORZIA has the potential to be an effective and convenient treatment option for peanut-allergic children aged 1 to 3 years.
  • POSEIDON enrolled 146 patients, with 98 randomized to PALFORZIA and 48 randomized to placebo.
  • Overall, 84.7% of patients on PALFORZIA and 93.8% of patients on placebo completed the study.

Medical Doctor in Chicago Launches Jamaican Coffee Company to "Give Back" to Those in Her Island Country Who Paved the Way for Her Success

Retrieved on: 
Jeudi, novembre 3, 2022
United Kingdom, Antioxidant, Guy's and St Thomas' NHS Foundation Trust, Lurie Children's Hospital, Ann, Institute, Hospital, Jackie Guy, Saint John, Cancer, Love, Gouais blanc, Inflammation, Coffee, Life, Type 2 diabetes, Degenerative disease, Genodermatosis, Dermatology

CHICAGO, Nov. 3, 2022 /PRNewswire/ -- Dr. Shardae Heinisch, a local pediatric dermatology fellow, who credits her island country of Jamaica with investing in her future, today will celebrate the one-year anniversary of her Jamaican coffee company, Mellow Royale Café, by being the first to introduce sorrel-infused coffee -- something no other coffee company has achieved. Heinisch also will donate a portion of her proceeds to the Jamaican Dermatology Healthcare System.

Key Points: 
  • Heinisch also will donate a portion of her proceeds to the Jamaican Dermatology Healthcare System.
  • Her plan was to return to Jamaica to put her training to work.
  • "I entered the medical field out of a genuine love for people, which prompted my desire to always find ways to give back," said Heinisch.
  • My goal is to donate proceeds from my endeavors to pay it forward and help others in need."